The combination of a GRPR antagonist and EGFR inhibitor showed antitumoral effects with a high proportion of apoptotic cells in HNSCC, suggesting that targeting GRPR could enhance treatment efficacy30. The gene discussed is GRPR; the disease is head and neck squamous cell carcinoma.